Cardiac point of care testing: A focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms

被引:46
作者
Christenson, Robert H. [1 ,2 ]
Azzazy, Hassan M. E. [3 ]
机构
[1] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med & Res Technol, Baltimore, MD 21201 USA
[3] Amer Univ Cairo, Res Ctr, Dept Chem & Youssef Jameel Sci & Technol, Cairo, Egypt
关键词
Point of care; Cardiac markers; Cardiac troponin; Guidelines; Acute coronary syndromes; Myocardial infarction; Risk stratification; MEDICINE PRACTICE GUIDELINES; ACUTE CORONARY SYNDROMES; TEST TURNAROUND TIME; CHEST-PAIN; EMERGENCY-DEPARTMENT; MYOCARDIAL-INFARCTION; RISK STRATIFICATION; TROPONIN-I; PROGNOSTIC VALUE; UNSTABLE ANGINA;
D O I
10.1016/j.clinbiochem.2008.09.105
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cardiac markers are a cornerstone for assessment of suspected acute coronary syndrome (ACS) patients. The National Academy for Clinical Biochemistry has recently developed practice guidelines for clinical, analytical and point-of-care (POC) testing in the context of ACS. Several technologies have become available for POC applications. Setting: Cardiac troponin is the preferred biochemical marker for diagnosis, risk stratification and guiding management of suspected ACS patients. Samples must be collected with proper timing, typically on presentation and then 6 to 9 h later. Assays should work toward a goal of total CV < 10% at the 99th percentile cutpoint, and should adhere to specifications defined by professional organizations. A 1-h or less turnaround time is specified; quantitative POC testing should be implemented if this timing cannot be met consistently by the central laboratory. The same quality criteria for assays apply regardless of testing venue. Implementation/management: Laboratory medicine personnel must have active role in implementation, choice of technology and management of POC cardiac marker testing. Conclusions: Cardiac troponin measurements at POC are a viable alternative when testing needs cannot be met by the central laboratory. Laboratory medicine must be involved in implementation and ongoing service. Quality of testing must not be compromised by performance at POC. (C) 2008 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:150 / 157
页数:8
相关论文
共 30 条
[1]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]   National Academy of Clinical Biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: Analytical issues for biomarkers of heart failure [J].
Apple, Fred S. ;
Wu, Alan H. B. ;
Jaffe, Allan S. ;
Panteghini, Mauro ;
Christenson, Robert H. .
CLINICAL BIOCHEMISTRY, 2008, 41 (4-5) :222-226
[3]   Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit [J].
Apple, Fred S. ;
Chung, Adrine Y. ;
Kogut, Mary Ellen ;
Bubany, Susan ;
Murakami, MaryAnn M. .
CLINICA CHIMICA ACTA, 2006, 370 (1-2) :191-195
[4]   Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction [J].
Apple, FS ;
Parvin, CA ;
Buechler, KF ;
Christenson, RH ;
Wu, AHB ;
Jaffe, AS .
CLINICAL CHEMISTRY, 2005, 51 (11) :2198-2200
[5]   Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome [J].
Apple, FS ;
Wu, AHB ;
Mair, J ;
Ravkilde, J ;
Panteghini, M ;
Tate, J ;
Pagani, F ;
Christenson, RH ;
Mockel, M ;
Danne, O ;
Jaffe, AS .
CLINICAL CHEMISTRY, 2005, 51 (05) :810-824
[6]   Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing? [J].
Azzazy, HME ;
Christenson, RH .
CLINICAL BIOCHEMISTRY, 2002, 35 (01) :13-27
[7]   Prodromal unstable angina in acute myocardial infarction: Prognostic value of short- and long-term outcome and predictor of infarct size [J].
Bahr, RD ;
Leino, EV ;
Christenson, RH .
AMERICAN HEART JOURNAL, 2000, 140 (01) :126-133
[8]  
Baxter MS, 1997, ACAD EMERG MED, V4, P1018
[9]   ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374
[10]  
Cohn P F, 1989, Adv Intern Med, V34, P377